Antimicrobial

NextStep Arthropedix to Launch TheRay™ Hip SystemNextStep Arthropedix to Launch TheRay™ Hip System

NextStep Arthropedix to Launch TheRay™ Hip System

NextStep Arthropedix, a growing orthopedics company, announces the launch of TheRay™ Collared and Collarless Hip System. AKRON, Ohio, July 15, 2024…

11 months ago
Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Recce Pharmaceuticals Reports Positive Data from Phase I/II Urinary Tract Infection (UTI) / Urosepsis Rapid Infusion Trial of RECCE® 327

Results demonstrate efficacy on bacterial growth in participants injected with RECCE® 327 (R327) at the highest tested dose of 4,000mgNo…

12 months ago
Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare GlobalKane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global

Kane Biotech Makes First Commercial Sale of revyve™ Antimicrobial Wound Gel to ProgenaCare Global

Kane Also Signs Long-Term Manufacturing Agreement With Halo PharmaWINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-…

12 months ago
Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteriaLilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria

Lilly collaborates with OpenAI to discover novel medicines to treat drug-resistant bacteria

INDIANAPOLIS, June 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced a collaboration with OpenAI that will allow…

12 months ago
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin InfectionsRecce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections

Positions RECCE® 327 (R327) gel as a potential broad topical therapeutic for all bacterial skin infectionsHuman Research Ethics Committee approval…

12 months ago
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical DevelopmentRecce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development

Inclusion underscores significance of RECCE® 327 (R327) in combating antimicrobial resistance and its potential to treat broad range of life-threatening…

12 months ago
AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARDAUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD

AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD

The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s…

12 months ago
Canopy expands real-time wearable safety from hospitals to home healthCanopy expands real-time wearable safety from hospitals to home health

Canopy expands real-time wearable safety from hospitals to home health

Leading health systems expand staff safety initiatives by deploying Canopy's real-time support network beyond hospital walls PALO ALTO, Calif., June…

12 months ago
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion TrialRecce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial

Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial

Six additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in…

1 year ago
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead CandidateOsteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate

Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate

Financing led by Zimmer Biomet with participation from existing investors Johnson & Johnson Innovation – JJDC, Inc., Gideon Strategic Partners,…

1 year ago